Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Oct 2, 2020

Keywords

ClinConnect Summary

This clinical trial, called EPIDROP, is studying a new way to detect cancer cells that are traveling in the blood of men with advanced (metastatic) prostate cancer. These traveling cancer cells, known as circulating tumor cells (CTCs), are important because they can help doctors understand how the cancer is spreading and how well treatments might be working. The trial is testing a new technology called EPIDROP, which looks at individual living cancer cells to see if they are active and producing a protein linked to prostate cancer. The goal is to see if this new test works as well as the current standard test.

Men who are eligible to join the study are those over 18 with metastatic prostate cancer who have not yet started treatment, or those whose cancer has returned after hormone therapy. The study is only for men since it focuses on prostate cancer. If you join, you can expect to give blood samples that will be tested using the EPIDROP method. This test involves looking closely at cells in the blood to detect and study live cancer cells. The study is currently recruiting participants and aims to improve how prostate cancer is monitored, which could help guide better treatment decisions in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria :
• • To be male, over 18 years old
• • Metastatic prostate cancer naive to any treatment or metastatic prostate cancer in biological recurrence (PSA increase) and/or clinical recurrence after hormone suppression (mCRPC)
• Exclusion Criteria:
• • Non-metastatic prostate cancer in biological and/or clinical recurrence after hormone-suppression (nmCRPC)
• • Other active or treated cancer less than 5 years old
• • Be protected by law (guardianship or curatorship)
• • Be deprived of liberty by administrative decision
• • Not being affiliated to a social security scheme, or not being a beneficiary of such a plan
• • Being in a period of exclusion from another protocol
• • Inability to understand and/or respond to questionnaires
• • Inability to understand the nature, purpose and methodology of the study
• • Refusal to sign informed consent